Consolidated Statements of Loss and Comprehensive Loss - USD ($)
|
12 Months Ended |
Mar. 31, 2022 |
Mar. 31, 2021 |
| Income Statement [Abstract] |
|
|
| Revenue from sales and services, net of excise taxes of $1,877,543 (2021 - $38,056) |
$ 47,695,828
|
$ 34,261,647
|
| Revenue from Contract with Customer, Product and Service [Extensible Enumeration] |
us-gaap:ProductMember, us-gaap:ServiceMember
|
us-gaap:ProductMember, us-gaap:ServiceMember
|
| Royalty revenues |
$ 1,019,861
|
$ 1,109,678
|
| Other revenues |
81,435
|
28,994
|
| Total revenues |
48,797,124
|
35,400,319
|
| Cost of sales other than loss on inventories, net of subsidies of $924,644 (2021 - $932,483 ) |
(52,561,404)
|
(30,964,709)
|
| Cost of services |
|
(12,846,937)
|
| Impairment loss on inventories |
(3,772,066)
|
(18,962,254)
|
| Total Cost of sales and services |
$ (56,333,470)
|
$ (62,773,900)
|
| Cost, Product and Service [Extensible Enumeration] |
us-gaap:ProductMember, us-gaap:ServiceMember
|
us-gaap:ProductMember, us-gaap:ServiceMember
|
| Gross profit (loss) |
$ (7,536,346)
|
$ (27,373,581)
|
| Research and development expenses, net of tax credits and grants of nil (2021 - $12,272 ) |
(880,151)
|
(1,922,195)
|
| Selling, general and administrative expenses, net of subsidies of $99,840 (2021 - $1,431,033 ) |
(60,538,424)
|
(63,824,118)
|
| Impairment loss related to intangible assets |
(1,527,000)
|
|
| Impairment loss related to property, plant and equipment |
(14,765,582)
|
(10,747,692)
|
| Impairment loss related to right-of-use assets |
|
(107,650)
|
| Impairment loss related to goodwill |
(3,288,847)
|
(26,898,016)
|
| Net gain on sale of assets |
6,469
|
|
| Loss from operating activities |
(88,529,881)
|
(130,873,252)
|
| Finance income |
7,123
|
825,745
|
| Finance costs |
(2,143,978)
|
(1,786,781)
|
| Foreign exchange loss |
(685,708)
|
(4,051,418)
|
| Change in revaluation of marketable securities |
(107,203)
|
169,216
|
| Gain on revaluation of derivatives |
7,035,118
|
7,974,549
|
| Nonoperating income (expense) |
4,105,352
|
3,131,311
|
| Loss before income tax |
(84,424,529)
|
(127,741,941)
|
| Income tax recovery |
|
3,477,711
|
| Net loss |
(84,424,529)
|
(124,264,230)
|
| Other comprehensive income |
|
|
| Net change in unrealized foreign currency gains on translation of net investments in foreign operations (tax effect of nil for both periods) |
750,248
|
6,737,947
|
| Total other comprehensive income |
750,248
|
6,737,947
|
| Total comprehensive loss |
(83,674,281)
|
(117,526,283)
|
| Net loss attributable to: |
|
|
| Net loss |
(74,971,745)
|
(123,170,020)
|
| Non-controlling interest |
(9,452,784)
|
(1,094,210)
|
| Net loss |
(84,424,529)
|
(124,264,230)
|
| Total comprehensive loss attributable to: |
|
|
| Equity holders of the Corporation |
(74,218,802)
|
(116,206,145)
|
| Non-controlling interest |
(9,455,479)
|
(1,320,138)
|
| Total comprehensive loss |
$ (83,674,281)
|
$ (117,526,283)
|
| Basic and diluted loss per share attributable to: |
|
|
| Equity holders of the Corporation, basic |
$ (15.54)
|
$ (35.55)
|
| Equity holders of the Corporation, diluted |
(15.54)
|
(35.55)
|
| Non-controlling interest, basic |
(1.96)
|
(0.32)
|
| Non-controlling interest, diluted |
(1.96)
|
(0.32)
|
| Total loss per share, basic |
(17.50)
|
(35.86)
|
| Total loss per share, diluted |
$ (17.50)
|
$ (35.86)
|
| Weighted average number of common shares, basic |
4,824,336
|
3,465,059
|
| Weighted average number of common shares, diluted |
4,824,336
|
3,465,059
|